Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - capecitabine - tablet, film coated - 150 mg - capecitabine 150 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose   iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose purified talc purified water   titanium dioxide - capecitabine winthrop is indicated for the treatment of patients with locally advanced or / metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine winthrop in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

United States - English - NLM (National Library of Medicine)

ecomine co., ltd. - dexpanthenol (unii: 1o6c93ri7z) (dexpanthenol - unii:1o6c93ri7z), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a), salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - dexpanthenol 0.002 in 100 ml

United States - English - NLM (National Library of Medicine)

ecomine co., ltd. - dexpanthenol (unii: 1o6c93ri7z) (dexpanthenol - unii:1o6c93ri7z), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a), salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - dexpanthenol 0.002 in 500 g - uses to recover the scalp condition for healthier hair. to strengthen hair root, give growth stimulation and thicken hair.

United States - English - NLM (National Library of Medicine)

ecomine co., ltd. - dexpanthenol (unii: 1o6c93ri7z) (dexpanthenol - unii:1o6c93ri7z), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a), salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - dexpanthenol 0.002 in 100 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 5 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; nicotinamide, quantity: 50 mg/ml; dexpanthenol, quantity: 10 mg/ml; pyridoxine hydrochloride, quantity: 25 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. patients requiring parenteral b vitamin therapy who cannot tolerate intramuscular injections. 5. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that iv b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 6. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2 and b6. 7. peripheral neuritis caused by vari

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 100 mg/ml; riboflavine sodium phosphate, quantity: 2 mg/ml; nicotinamide, quantity: 20 mg/ml; dexpanthenol, quantity: 20 mg/ml; pyridoxine hydrochloride, quantity: 40 mg/ml; cyanocobalamin, quantity: 0.4 mg/ml - injection, solution - excipient ingredients: disodium edetate; benzyl alcohol; water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7. carpal tunnel syndrome. 8. pernicious anaemia as a result of in situ b12 deficiency. general indications include: 1. angular stomatitis and glossitis have been shown in some instances to respond to t

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - capecitabine - tablet, film coated - 150mg - capecitabine 150mg

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow lactose macrogol 8000 magnesium stearate methylcellulose titanium dioxide - breast cancer capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. colon cancer capecitabine is indicated for the adjuvant treatment of patients with dukes' stage c and high risk stage b colon cancer, either as monotherapy or in combination with oxaliplatin. colorectal cancer capecitabine is indicated for first-line treatment of patients with metastatic colorectal cancer. oesophagogastric cancer capecitabine is indicated for the first line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - capecitabine 150mg;  ;   - film coated tablet - 150 mg - active: capecitabine 150mg     excipient: croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 04f54305 - capecitabine tablets are indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine tablets in combination with docetaxel are indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.